Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

نتائج البحث

Display Settings
النتائج لكل صفحة: 10
Sort By: Relevance
Filter
  • 1-9 ل  9 نتائج ل ""Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores]""

فلترة النتائج

Subject : antineoplastic combined chemotherapy protocols
إعادة تعيين خيارات الفبترة
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Metastatic Rhabdomyosarcoma: Results of the European Paediatric Soft Tissue Sarcoma Study Group MTS 2008 Study and Pooled Analysis With the Concurrent BERNIE Study

Subjects: Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]; Other subheadings::Other subheadings::/drug therapy [Other subheadings]; neoplasias::neoplasias por tipo histológico::neoplasias de tejido conjuntivo y de tejidos blandos::neoplasias de tejido muscular::miosarcoma::rabdomiosarcoma [ENFERMEDADES]

  • Source: J Clin OncolScientia

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

Subjects: Diarrhea; Receptor, ErbB-2; Science

  • Source: Nat CommunNature Communications, Vol 14, Iss 1, Pp 1-12 (2023)Scientia

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer

Subjects: 0301 basic medicine; Maximum Tolerated Dose; Paclitaxel

  • Source: Clin Cancer ResCLINICAL CANCER RESEARCHr-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstnameScientiaClinical Cancer ResearchClinical

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial

Subjects: Paclitaxel; Class I Phosphatidylinositol 3-Kinases; Receptor, ErbB-2

  • Source: Breast Cancer Res TreatScientia

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors

Subjects: Male; 0301 basic medicine; Maximum Tolerated Dose

  • Source: ANNALS OF ONCOLOGYr-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVAinstnameAnnals of oncology : official journal of the European Society for Medical

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial

Subjects: Receptor, ErbB-2; Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES]; Breast Neoplasms

  • Source: JAMA OncolU. Lin, N, K. Murthy, R, Abramson, V, Anders, C, Bachelot, T, L. Bedard, P, Borges, V, Cameron, D A, A. Carey, L, Chien, J, Curigliano, G, P. Di Giovanna, M, Gelmon, K, Hortobagyi, G,

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study

Subjects: Proto-Oncogene Proteins B-raf; Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]; Cetuximab

  • Source: ESMO OpenScientia

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Trifluridine/tipiracil in combination with oxaliplatin and either bevacizumab or nivolumab in metastatic colorectal cancer: a dose-expansion, phase I study

Subjects: Pyrrolidines; Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]; [SDV.CAN]Life Sciences [q-bio]/Cancer

  • Source: ESMO OpenRepositorio Institucional de la Consejería de Sanidad de la Comunidad de MadridConsejería de Sanidad de la Comunidad de MadridESMO Open, 2021, 6 (5), pp.100270.

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
Academic Journal

Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

Subjects: glicoles de polietileno; Polietilenglicoles; Doxorrubicina

  • Source: BMC MedDocusalutConselleria de Salut i Consum del Govern de les Illes BalearsDipòsit Digital de la UBUniversidad de BarcelonaBMC MEDICINEr-FISABIO. Repositorio

تفاصيل العنوان

اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
×
  • 1-9 ل  9 نتائج ل ""Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores]""